Markerless Kinematics of Levodopa Response During Activities of Daily Living in Parkinson’s Disease
Objective: To determine whether markerless motion tracking during activities of daily living (ADLs) can identify kinematic changes during medication wearing-off as Parkinson's disease (PD) patients…External Validation of Reported Clinical Predictors of Levodopa-Related Adverse Drug Reactions in Parkinson’s Disease
Objective: To assess the predictive value of previously reported clinical and demographic predictors for levodopa-related adverse drug reactions in the Dutch multicenter Profiling Parkinson’s disease…Psychosis in Parkinson’s Disease Patients Treated with Continuous Subcutaneous Foslevodopa/Foscarbidopa: A Real-World Observational Study.
Objective: To assess the incidence and timing of psychosis (hallucinations and delusions) in Parkinson’s disease patients receiving continuous subcutaneous infusion of foslevodopa/foscarbidopa (CSFLI). Background: CSFLI…The Effect of Levodopa on Calpain Activity in Patients with Parkinson’s Disease
Objective: The objective of this report is to investigate the effect of Levodopa therapy on calpain activity in patients with advanced stages of Parkinson's disease to…Switching to IPX203 Significantly Increases the Duration of “Good On” Intervals: Interim Real-World Results from the First 111 Patients in ELEVATE-PD
Objective: Evaluate the impact of IPX203 on the duration of “Good On” intervals and daily motor fluctuations in patients with PD after switching from other…Deep brain stimulation improves levodopa-induced dyskinesias beyond medication reduction in Parkinson’s disease
Objective: To determine whether the improvement in levodopa-induced dyskinesias after deep brain stimulation is primarily associated with reduction in dopaminergic medication or with a direct…Predicting Levodopa Responsiveness in Early Parkinson’s Disease Using Neural Perturbation Inference-Based Effective Connectivity
Objective: To investigate the brain network mechanisms underlying individual variability in levodopa responsiveness in Parkinson’s disease (PD) and to evaluate the predictive value of baseline…SLC20A2 Splice-Site Mutation (c.935-1G>A) Presenting as levodopa-responsive parkinsonism: Expanding the Phenotypic Spectrum of Primary Familial Brain Calcification
Objective: To report a case carrying a rare splice-site mutation in the SLC20A2 gene presenting as early-onset, levodopa-responsive parkinsonism. Background: Primary Familial Brain Calcification (PFBC)…Reduction in Dopaminergic Medication in Patients with Parkinson’s Disease Treated with Continuous Apomorphine Infusion versus Subthalamic Nucleus Deep Brain Stimulation: A Cohort Study
Objective: To compare the reduction in levodopa equivalent daily dose (LEDD) in patients with Parkinson’s disease treated with continuous subcutaneous apomorphine infusion versus bilateral subthalamic…A Case Report: Optimising Motor and Non-Motor Control in Advanced Parkinson’s Disease: The Role of Foslevodopa/Foscarbidopa After Deep Brain Stimulation
Objective: To investigate the combined use of continuous subcutaneous foslevodopa/foscarbidopa and deep-brain stimulation in managing advanced Parkinsons Disease. Background: Continuous foslevodopa/foscarbidopa subcutaneous (SC) infusion has been shown…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 70
- Next Page »